title: Cancer-drug discovery and cardiovascular surveillance.
authors.affiliation: From the Cardio-Oncology Program at the Dana-Farber Cancer Institute (J.D.G., J.M.) and the Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital (J.D.G., S.C., J.M.); and Harvard Medical School (J.D.G., S.C., J.M.) - all in Boston.
authors.forename: John D
authors.initials: JD
authors.lastname: Groarke
authors.forename: Susan
authors.initials: S
authors.lastname: Cheng
authors.forename: Javid
authors.initials: J
authors.lastname: Moslehi
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D002319:Cardiovascular System / Q000187:drug effects; D055808:Drug Discovery; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000235:genetics; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics; D011724:Pyridazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D014652:Vascular Diseases / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; D011743:Pyrimidines; C545373:ponatinib; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib